CL2017002709A1 - Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr - Google Patents

Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr

Info

Publication number
CL2017002709A1
CL2017002709A1 CL2017002709A CL2017002709A CL2017002709A1 CL 2017002709 A1 CL2017002709 A1 CL 2017002709A1 CL 2017002709 A CL2017002709 A CL 2017002709A CL 2017002709 A CL2017002709 A CL 2017002709A CL 2017002709 A1 CL2017002709 A1 CL 2017002709A1
Authority
CL
Chile
Prior art keywords
compounds
triazolo
pyrazolo
vsr
pyrimidine
Prior art date
Application number
CL2017002709A
Other languages
English (en)
Inventor
Pierre Jean-Marie Bernard Raboisson
David Francis Alain Lançois
Jérôme Émile Georges Guillemont
Dirk André Emmy Roymans
Boris Rogovoy
Vadim Bichko
Delphine Yvonne Raymonde Lardeau
Antoine Benjamin Michaut
Anil Koul
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CL2017002709A1 publication Critical patent/CL2017002709A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención se refiere a compuestos de pirazolo- y triazolo-pirimidina sustituidos novedosos de fórmula (I) que tienen actividad antiviral, en particular, que tienen una actividad inhibidora sobre la replicación del virus sincitial respiratorio (VSR). La invención se refiere además a composiciones farmacéuticas que comprenden estos compuestos y a los compuestos para su uso en el tratamiento de la infección por el virus sincitial respiratorio.</p>
CL2017002709A 2015-04-28 2017-10-25 Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr CL2017002709A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153753P 2015-04-28 2015-04-28
US201562204390P 2015-08-12 2015-08-12

Publications (1)

Publication Number Publication Date
CL2017002709A1 true CL2017002709A1 (es) 2018-04-20

Family

ID=55860847

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002709A CL2017002709A1 (es) 2015-04-28 2017-10-25 Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr

Country Status (29)

Country Link
US (3) US10208048B2 (es)
EP (1) EP3288942B1 (es)
JP (1) JP6698693B2 (es)
KR (1) KR102538565B1 (es)
CN (1) CN107531715B (es)
AU (1) AU2016254700B2 (es)
BR (1) BR112017023263B1 (es)
CA (1) CA2981404C (es)
CL (1) CL2017002709A1 (es)
CY (1) CY1125329T1 (es)
DK (1) DK3288942T3 (es)
EA (1) EA035689B1 (es)
ES (1) ES2905550T3 (es)
HR (1) HRP20211728T1 (es)
HU (1) HUE057626T2 (es)
IL (1) IL254750B (es)
JO (1) JO3637B1 (es)
LT (1) LT3288942T (es)
MA (1) MA41974A (es)
MX (1) MX369040B (es)
PH (1) PH12017501958A1 (es)
PL (1) PL3288942T3 (es)
PT (1) PT3288942T (es)
SG (1) SG11201708786SA (es)
SI (1) SI3288942T1 (es)
TW (1) TWI703146B (es)
UA (1) UA120448C2 (es)
WO (1) WO2016174079A1 (es)
ZA (1) ZA201707320B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TW201932470A (zh) * 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
TW201936193A (zh) 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
CA3087926A1 (en) 2018-01-31 2019-08-08 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
AU2019260109B2 (en) * 2018-04-23 2023-07-13 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
CA3099311A1 (en) * 2018-05-03 2019-11-07 Georgia State University Research Foundation, Inc. Inhibitors of rsv replication and applications thereof
US20220033396A1 (en) * 2018-11-26 2022-02-03 Janssen Sciences Ireland Unlimited Company Further heteroaromatic compounds having activity against rsv
WO2020138015A1 (ja) 2018-12-27 2020-07-02 大正製薬株式会社 ピラゾロ［１，５－ａ］ピリミジン大環状化合物
US20240158390A1 (en) 2019-05-23 2024-05-16 Janssen Sciences Ireland Unlimited Company Other heteroaromatic compounds having activity against rsv
CN111440173B (zh) * 2020-03-27 2021-05-14 山东大学 一种pi3k抑制剂的制备方法
WO2022020889A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Method of treatment of cytomegalovirus
WO2022020891A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Methods of prophylaxis and treatment of corona virus
TWI839652B (zh) 2020-10-28 2024-04-21 日商鹽野義製藥股份有限公司 具有抗病毒活性的醯胺衍生物
AU2022217264A1 (en) 2021-02-08 2023-09-14 The Trustees Of Columbia University In The City Of New York Oxa-ibogaine inspired analogues for treatment of neurological and psychiatric disorders
CN116425754A (zh) * 2021-12-30 2023-07-14 苏州爱科百发生物医药技术有限公司 芳杂双环化合物及其抗病毒用途
WO2023245166A2 (en) * 2022-06-17 2023-12-21 Trawsfynydd Therapeutics, Inc. Compounds for treatment of a coronavirus infection
WO2024121264A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121261A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121262A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121263A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2026003049A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003043A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1175259A (zh) 1994-12-22 1998-03-04 生化制药有限公司 低分子量双环凝血酶抑制剂
WO1997001275A1 (en) 1995-06-29 1997-01-16 Merck & Co., Inc. Combinations of inhibitors of farnesyl-protein transferase
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972966A (en) 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
KR20020063837A (ko) 1999-07-19 2002-08-05 시오노기세이야쿠가부시키가이샤 아실옥시메톡시카르보닐 측쇄를 갖는 삼환 화합물
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2003016274A2 (en) 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
EP1560573B1 (en) 2002-09-20 2008-12-03 Medisyn Technologies, Inc. Use of n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicyclo[2.2.1]hept-1-ylmethanesulfonamide family members in therapy
EP1546132A1 (en) 2002-09-26 2005-06-29 Pfizer Limited Pyrazole derivatives as reverse transcriptase inhibitors
WO2004037817A1 (ja) 2002-10-25 2004-05-06 Mitsubishi Pharma Corporation Ｎ−オキシド化合物
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
WO2005042530A1 (en) 2003-10-30 2005-05-12 Boehringer Ingelheim (Canada) Ltd. Rsv polymerase inhibitors
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
CA2551178C (en) 2003-12-24 2012-11-06 Biota Scientific Management Pty Ltd Polycyclic agents for the treatment of respiratory syncytial virus infections
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
AU2006260969B2 (en) * 2005-06-20 2011-11-17 Janssen Sciences Ireland Uc 1- ( 2-amino-3- (substituted alkyl)-3H-benzimidazolylmethyl) -3-substituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
CN101360736A (zh) 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-丙氨酸衍生物
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
US20080176870A1 (en) 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
CN101842098A (zh) 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
AR073739A1 (es) 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
CA2738453C (en) 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
WO2010104306A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2010111058A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
EP2853531A3 (en) 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CN102958933B (zh) * 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
WO2012100342A1 (en) * 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
EA027855B1 (ru) * 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Соединения и способы для противовирусной терапии
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
CN107108556B (zh) 2014-11-03 2020-09-29 艾欧米制药有限公司 药用化合物
AU2015359624B2 (en) 2014-12-08 2020-01-02 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv

Also Published As

Publication number Publication date
SI3288942T1 (sl) 2022-01-31
JP2018514544A (ja) 2018-06-07
PT3288942T (pt) 2021-12-17
US10208048B2 (en) 2019-02-19
CN107531715A (zh) 2018-01-02
TW201708227A (zh) 2017-03-01
DK3288942T3 (da) 2022-01-17
HUE057626T2 (hu) 2022-05-28
US20190248793A1 (en) 2019-08-15
CN107531715B (zh) 2021-03-30
KR20170139122A (ko) 2017-12-18
AU2016254700B2 (en) 2020-01-02
ES2905550T3 (es) 2022-04-11
US10611769B2 (en) 2020-04-07
EA201792370A1 (ru) 2018-02-28
CA2981404C (en) 2023-09-19
MA41974A (fr) 2018-03-07
SG11201708786SA (en) 2017-11-29
US11084826B2 (en) 2021-08-10
PH12017501958B1 (en) 2018-03-26
TWI703146B (zh) 2020-09-01
IL254750A0 (en) 2017-11-30
MX369040B (es) 2019-10-25
HRP20211728T1 (hr) 2022-02-18
US20180105529A1 (en) 2018-04-19
ZA201707320B (en) 2020-08-26
IL254750B (en) 2020-07-30
MX2017013884A (es) 2018-03-16
AU2016254700A1 (en) 2017-10-19
EA035689B1 (ru) 2020-07-27
UA120448C2 (uk) 2019-12-10
JO3637B1 (ar) 2020-08-27
BR112017023263B1 (pt) 2023-04-11
CY1125329T1 (el) 2024-02-16
EP3288942A1 (en) 2018-03-07
EP3288942B1 (en) 2021-10-27
LT3288942T (lt) 2021-12-10
WO2016174079A1 (en) 2016-11-03
KR102538565B1 (ko) 2023-05-30
BR112017023263A2 (pt) 2018-08-07
PH12017501958A1 (en) 2018-03-26
US20200223855A1 (en) 2020-07-16
HK1248230A1 (zh) 2018-10-12
CA2981404A1 (en) 2016-11-03
PL3288942T3 (pl) 2022-02-21
JP6698693B2 (ja) 2020-05-27

Similar Documents

Publication Publication Date Title
CY1125329T1 (el) Αντιιικες ενωσεις πυραζολο- και τριαζολο-πυριμιδινης εναντι toy rsv
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
NZ733174A (en) Quinazoline derivatives used to treat hiv
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
CL2020001353A1 (es) Pirazolopirimidinas que tienen actividad contra el vsr.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201790495A1 (ru) Фармацевтические композиции длительного действия
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas